Standout Papers

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inh... 2012 2026 2016 2021 489
  1. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer (2012)
    Andrew Weickhardt, Benjamin Scheier et al. Journal of Thoracic Oncology

Immediate Impact

1 from Science/Nature 74 standout
Sub-graph 1 of 21

Citing Papers

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
5 intermediate papers

Works of Joseph Burke being referenced

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
2012 Standout
Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC).
2012

Author Peers

Author Last Decade Papers Cites
Joseph Burke 36 481 387 97 7 551
KEIICHI SUEMASU 17 498 221 87 8 638
Isabelle Gauthier 20 295 274 212 11 569
Andrew K. Chung 24 274 198 84 9 495
Terence Rugg 8 257 290 121 5 469
Yenting Ngai 35 376 268 76 17 544
Y. Nakanishi 5 435 230 109 7 608
Sharma P. Riaz 15 301 312 60 9 509
Nathalie Syz 5 281 276 59 5 476
Maria Cristina Bruna 9 254 234 32 13 471
Jean-François Caubet 21 247 197 113 8 460

All Works

Loading papers...

Rankless by CCL
2026